1. Background
2. Objectives
3. Methods
4. Results
| Variables | Without Urinary Tract Infection (n = 218) | With Urinary Tract Infection (n = 50) | OR (95% CI) | P-Value |
|---|---|---|---|---|
| Age (y) | 44.4 ± 13.1 | 43.4 ± 12.9 | 1.001 | 0.833 |
| Sex | 3.842 | < 0.001 | ||
| Male | 171 (89) | 23 (11) | ||
| Female | 47 (63) | 27 (37) | ||
| Location | 0.722 | 0.377 | ||
| The center of province | 138 (80) | 36 (20) | ||
| Others | 80 (85) | 14 (15) | ||
| Underlying cause | ||||
| Diabetes mellitus | 54 (90) | 6 (10) | 0.406 | 0.061 |
| Hypertension | 37 (80) | 9 (20) | 1.050 | 0.091 |
| Polycystic kidney | 21 (80) | 5 (20) | 1.101 | 0.276 |
| Primary glomerulonephritis | 21 (100) | 0 (0) | - | 0.998 |
| Unknown cause | 60 (81) | 14 (19) | 1.027 | 0.052 |
| Others b (Analgesic nephropathy, renal stone, reflux nephropathy, lupus nephritis) | 25 (60) | 16 (40) | 3.716 | 0.041 |
| Number of transplantations | 1.348 | 0.726 | ||
| 1 | 208 (81) | 46 (19) | ||
| 2 | 10 (71) | 4 (29) | ||
| Type of donor | 1.764 | 0.147 | ||
| Living donor | 148 (84) | 27 (16) | ||
| Cadaveric donor | 70 (75) | 23 (25) | ||
| History of pre-transplant dialysis | 0.463 | 0.602 | ||
| Yes | 204 (80) | 48 (20) | ||
| No | 14 (87) | 2 (13) | ||
| Type of pre-transplant dialysis | 0.818 | 0.793 | ||
| Hemodialysis | 175 (81) | 40 (19) | ||
| Peritoneal-dialysis | 29 (78) | 8 (22) |
a Values are expressed as mean ± SD or No. (%).
b See Table 2.
| Disease | Without Urinary Tract Infection (n = 25) | With Urinary Tract Infection (n = 16) |
|---|---|---|
| Analgesic nephropathy | 0 | 2 (100) |
| Renal stone | 4 (66.7) | 2 (33.3) |
| Reflux nephropathy | 15 (75) | 5 (25) |
| Lupus nephritis | 6 (46.2) | 7 (53.8) |
a Values are expressed as mean ± SD or No. (%).
| Microorganisms | Urinary Tract Infection |
|---|---|
| Escherichia coli | 31 (58.4) |
| Enterobacter | 6 (11.3) |
| Coagulase negative Staphylococcus | 6 (11.3) |
| Klebsiella | 2 (3.7) |
| Streptococcus | 3 (5.6) |
| Proteus | 3 (5.6) |
| Fungal | 2 (3.7) |
| Total | 53 (100) |
a Values are expressed as mean ± SD or No. (%).
| Antibiotics | Proteus | Streptococcus | Klebsiella | Coagulase negative Staphylococcus | Enterobacter | Escherichia coli | Fungal |
|---|---|---|---|---|---|---|---|
| Amikacin | 2 (20) | 0 | 2 (25) | 0 | 3 (17.6) | 8 (8.1) | 0 |
| Kanamycin | 0 | 0 | 0 | 0 | 1 (5.8) | 0 | 0 |
| Nitrofurantoin | 0 | 2 (40) | 0 | 1 (6.6) | 4 (23.5) | 17 (17.3) | 0 |
| Co-trimoxazole | 0 | 0 | 0 | 0 | 4 (23.5) | 1 (1.02) | 0 |
| Cefixime | 0 | 1 (20) | 0 | 4 (26.6) | 0 | 4 (4.08) | 0 |
| Meropenem | 1 (10) | 2 (40) | 0 | 6 (40) | 3 (17.6) | 14 (14.2) | 0 |
| Cefazolin | 0 | 0 | 2 (25) | 0 | 0 | 1 (1.02) | 0 |
| Cefalotin | 0 | 0 | 2 (25) | 0 | 0 | 1 (1.02) | 0 |
| Imipenem | 2 (20) | 0 | 1 (12.5) | 0 | 2 (11.7) | 9 (9.1) | 0 |
| Ciprofloxacin | 0 | 0 | 1 (12.5) | 1 (6.6) | 0 | 10 (10.02) | 0 |
| Itraconazole | 0 | 0 | 0 | 0 | 0 | 0 | 2 (100) |
| Ofloxacin | 0 | 0 | 0 | 0 | 0 | 10 (10.02) | 0 |
| Ceftriaxone | 2 (20) | 0 | 0 | 0 | 0 | 9 (9.1) | 0 |
| Ceftazidime | 3 (30) | 0 | 0 | 0 | 0 | 6 (6.12) | 0 |
| Ceftizoxime | 0 | 0 | 0 | 0 | 0 | 1 (1.02) | 0 |
| Vancomycin | 0 | 0 | 0 | 3 (20) | 0 | 4 (4.08) | 0 |
| Cefotaxime | 0 | 0 | 0 | 0 | 0 | 2 (2.04) | 0 |
| Cephalexin | 0 | 0 | 0 | 0 | 0 | 1 (1.02) | 0 |
| Total | 10 (100) | 5 (100) | 8 (100) | 15 (100) | 17 (100) | 98 (100) | 2 (100) 100 100 100 100 |
a Values are expressed as mean ± SD or No. (%).